genOway Société anonyme Valuation

Is ALGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALGEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALGEN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALGEN?

Key metric: As ALGEN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALGEN. This is calculated by dividing ALGEN's market cap by their current earnings.
What is ALGEN's PE Ratio?
PE Ratio	26.9x
Earnings	€1.26m
Market Cap	€33.79m

ALGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	6.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does ALGEN's PE Ratio compare to its peers?

The above table shows the PE ratio for ALGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	16.3x
OSE OSE Immunotherapeutics	4.1x	-72.5%	€188.8m
GNFT Genfit	9x	41.2%	€200.4m
ALERS Eurobio Scientific Société anonyme	38.9x	29.0%	€258.6m
ALECR Eurofins-Cerep	13.1x	n/a	€99.9m
ALGEN genOway Société anonyme	26.9x	n/a	€33.8m

Price-To-Earnings vs Peers: ALGEN is expensive based on its Price-To-Earnings Ratio (26.9x) compared to the peer average (16.3x).

Price to Earnings Ratio vs Industry

How does ALGEN's PE Ratio compare vs other companies in the European Biotechs Industry?

5 Companies	Price / Earnings	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ALGEN is good value based on its Price-To-Earnings Ratio (26.9x) compared to the European Biotechs industry average (27x).

Price to Earnings Ratio vs Fair Ratio

What is ALGEN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALGEN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	26.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ALGEN's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Euroapi

€325.6m

Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use.

EAPI

€3.42

-2.9%

-37.5%

Sanofi

€113.9b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€90.87

-3.7%

5.4%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.51

0.4%

-57.1%